Management of the Cardiorenal Syndrome in Acute Heart Failure

Heart Failure (J Fang, Section Editor)

Opinion statement

Interactions between the heart and kidney in the setting of acute heart failure are complex and have a substantial impact on patient care and outcomes. Further research is needed to better distinguish the different causes of kidney injury, allow its early and accurate prediction and detection, and identify therapeutic targets. Novel renal biomarkers could potentially provide a useful tool for this purpose. Restoration of optimal fluid status and resolution of renal venous congestion are important goals of therapy. Changes in serum creatinine, although an important marker of renal function, may not be associated with adverse outcomes, especially if they are transient and a consequence of more aggressive decongestion, or the appropriate titration of drugs affecting the renin-angiotensin-aldosterone axis. In addition to loop diuretics, a variety of drugs and strategies have been investigated in acute heart failure. Use of mineralocorticoid receptor antagonists and vasopressin antagonists may have potential benefits and should be further investigated. Inotropic agents should be limited in those clinical settings suggesting hypoperfusion. Ultrafiltration seems to provide a safe and effective tool to overcome diuretic resistance and optimize fluid status avoiding detrimental effects of diuretic therapy.


Cardiorenal syndrome Acute heart failure Worsening renal function 

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Ronco C, McCullough PA, Anker SD, Acute Dialysis Quality Initiative (ADQI) consensus group, et al. Cardiorenal syndromes: an executive summary from the consensus conference of the Acute Dialysis Quality Initiative (ADQI). Contrib Nephrol. 2010;165:54–67. Epub 2010 Apr 20.PubMedCrossRefGoogle Scholar
  2. 2.
    Gottlieb SS, Abraham W, Butler J, et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail. 2002;8(3):136–41.PubMedCrossRefGoogle Scholar
  3. 3.
    Butler J, Chirovsky D, Phatak H, et al. Renal function, health outcomes, and resource utilization in acute heart failure: a systematic review. Circ Heart Fail. 2010;3(6):726–45.PubMedCrossRefGoogle Scholar
  4. 4.
    Breidthardt T, Socrates T, Noveanu M, et al. Effect and clinical prediction of worsening renal function in acute decompensated heart failure. Am J Cardiol. 2011;107(5):730–5. Epub 2011 Jan 19.PubMedCrossRefGoogle Scholar
  5. 5.
    Forman DE, Butler J, Wang Y, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004;43(1):61–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Heywood JT, Fonarow GC, Costanzo MR, ADHERE Scientific Advisory Committee and Investigators, et al. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail. 2007;13(6):422–30.PubMedCrossRefGoogle Scholar
  7. 7.
    Nohria A, Hasselblad V, Stebbins A, et al. Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol. 2008;51(13):1268–74.PubMedCrossRefGoogle Scholar
  8. 8.
    Damman K, Voors AA, Navis G, et al.: Current and novel renal biomarkers in heart failure. Heart Fail Rev. 2011 May 22. [Epub ahead of print]Google Scholar
  9. 9.
    Andreev E, Koopman M, Arisz L. A rise in plasma creatinine that is not a sign of renal failure: which drugs can be responsible? J Intern Med. 1999;246:247–52.PubMedCrossRefGoogle Scholar
  10. 10.
    Hunt SA, Abraham WT, Chin MH, American College of Cardiology Foundation; American Heart Association, et al. Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009;53(15):e1–e90.PubMedCrossRefGoogle Scholar
  11. 11.
    Testani JM, Kimmel SE, Dries DL, Coca SG. Prognostic importance of early worsening renal function after initiation of Angiotensin-converting enzyme inhibitor therapy in patients with cardiac dysfunction. Circ Heart Fail. 2011;4(6):685–91. Epub 2011 Sep 8.PubMedCrossRefGoogle Scholar
  12. 12.
    Butler J, Chirovsky D, Phatak H, et al. Renal function, health outcomes, and resource utilization in acute heart failure: a systematic review. Circ Heart Fail. 2010;3(6):726–45.PubMedCrossRefGoogle Scholar
  13. 13.
    Damman K, Navis G, Voors AA, et al. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail. 2007;13(8):599–608.PubMedCrossRefGoogle Scholar
  14. 14.••
    Damman K, Ng Kam Chuen MJ, MacFadyen RJ, et al.: Volume status and diuretic therapy in systolic heart failure and the detection of early abnormalities in renal and tubular function. J Am Coll Cardiol. 2011;57(22):2233–41. This study assessed the effect of furosemide withdrawal in a small cohort of patients with euvolemic status on markers of renal and tubular function and congestion. Diuretic withdrawal and subsequent subclinical congestion was associated with an increase in markers of tubular dysfunction, while restoration of fluid balance with a decrease PubMedCrossRefGoogle Scholar
  15. 15.•
    Blair JE, Pang PS, Schrier RW, et al.; EVEREST Investigators. Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. Eur Heart J. 2011;32(20):2563–72. Epub 2011 Jul 23. This retrospective analysis on the placebo group of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) characterizes a large cohort of patients with WRF during AHF. WRF was associated with poorer outcome but also with a significant decrease in markers of congestion.Google Scholar
  16. 16.
    Testani JM, Chen J, McCauley BD, Kimmel SE, Shannon RP. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation. 2010;122(3):265–72. Epub 2010 Jul 6.PubMedCrossRefGoogle Scholar
  17. 17.
    Testani JM, McCauley BD, Chen J, et al. Clinical characteristics and outcomes of patients with improvement in renal function during the treatment of decompensated heart failure. J Card Fail. 2011;17(12):993–1000. Epub 2011 Oct 1.PubMedCrossRefGoogle Scholar
  18. 18.
    Metra M, Davison B, Bettari L, et al. Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function. Circ Heart Fail. 2012;5(1):54–62. Epub 2011 Dec 13.PubMedCrossRefGoogle Scholar
  19. 19.
    Teerlink JR, Metra M, Felker GM, et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet. 2009;373(9673):1429–39. Epub 2009 Mar 28.PubMedCrossRefGoogle Scholar
  20. 20.
    Mullens W, Abrahams Z, Francis GS, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009;53(7):589–96.PubMedCrossRefGoogle Scholar
  21. 21.
    Damman K, Navis G, Smilde TD, et al. Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. Eur J Heart Fail. 2007;9(9):872–8. Epub 2007 Jun 22.PubMedCrossRefGoogle Scholar
  22. 22.
    Grams ME, Estrella MM, Coresh J, et al. Fluid balance, diuretic use, and mortality in acute kidney injury. Clin J Am Soc Nephrol. 2011;6(5):966–73. Epub 2011 Mar 10.PubMedCrossRefGoogle Scholar
  23. 23.
    Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis. 2002;40(2):221–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Shlipak MG, Katz R, Fried LF, et al. Cystatin-C and mortality in elderly persons with heart failure. J Am Coll Cardiol. 2005;45(2):268–71.PubMedCrossRefGoogle Scholar
  25. 25.
    Damman K, van der Harst P, Smilde TD, et al. Use of cystatin C levels in estimating renal function and prognosis in patients with chronic systolic heart failure. Heart. 2011 Oct 29. [Epub ahead of print]Google Scholar
  26. 26.
    Lassus J, Harjola VP, Sund R, for the FINN-AKVA Study group, et al. Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. Eur Heart J. 2007;28(15):1841–7. Epub 2007 Feb 8.PubMedCrossRefGoogle Scholar
  27. 27.
    Lassus JP, Nieminen MS, Peuhkurinen K, FINN-AKVA study group, et al. Markers of renal function and acute kidney injury in acute heart failure: definitions and impact on outcomes of the cardiorenal syndrome. Eur Heart J. 2010;31(22):2791–8. Epub 2010 Aug 27.PubMedCrossRefGoogle Scholar
  28. 28.
    Damman K, Van Veldhuisen DJ, Navis G, et al. Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate. Heart. 2010;96(16):1297–302.PubMedCrossRefGoogle Scholar
  29. 29.
    Alvelos M, Lourenço P, Dias C, et al. Prognostic value of neutrophil gelatinase-associated lipocalin in acute heart failure. Int J Cardiol. 2011 Aug 26. [Epub ahead of print]Google Scholar
  30. 30.
    Nymo SH, Ueland T, Askevold ET, et al. The association between neutrophil gelatinase-associated lipocalin and clinical outcome in chronic heart failure: results from CORONA(*).J Intern Med. 2011 Dec 28. doi:10.1111/j.1365-2796.2011.02503.x. [Epub ahead of print]
  31. 31.
    Damman K, Masson S, Hillege HL, et al. Clinical outcome of renal tubular damage in chronic heart failure. Eur Heart J. 2011;32(21):2705–12. Epub 2011 Jun 11.PubMedCrossRefGoogle Scholar
  32. 32.
    Maisel AS, Mueller C, Fitzgerald R, et al. Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: the NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial. Eur J Heart Fail. 2011;13(8):846–51.PubMedCrossRefGoogle Scholar
  33. 33.
    Aghel A, Shrestha K, Mullens W, et al. Serum neutrophil gelatinase-associated lipocalin (NGAL) in predicting worsening renal function in acute decompensated heart failure. J Card Fail. 2010;16(1):49–54. Epub 2009 Aug 21.PubMedCrossRefGoogle Scholar
  34. 34.
    Breidthardt T, Socrates T, Drexler B, et al. Plasma neutrophil gelatinase-associated lipocalin for the prediction of acute kidney injury in acute heart failure. Crit Care. 2012;16(1):R2 [Epub ahead of print].PubMedCrossRefGoogle Scholar
  35. 35.
    Dupont M, Awad A, Scarcipino M, et al. Rise in Urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL) Following Intravenous Diuretic Therapy Predicts Development of Worsening Renal Function in Acute Decompensated Heart Failure. Journal of Cardiac Failure, Volume 17, Issue 8, Supplement, August 2011, Pages S24–S25 [abstract]Google Scholar
  36. 36.
    Collins S, Sperling M, Storrow A, et al., Urinary NGAL Levels Predict Acute Kidney Injury in Emergency Department Patients with Acute Heart Failure, Journal of Cardiac Failure, Volume 16, Issue 8, Supplement, August 2010, Pages S29–S30 [abstract]Google Scholar
  37. 37.
    Jungbauer CG, Birner C, Jung B, et al. Kidney injury molecule-1 and N-acetyl-β-D-glucosaminidase in chronic heart failure: possible biomarkers of cardiorenal syndrome. Eur J Heart Fail. 2011;13(10):1104–10. Epub 2011 Aug 16.PubMedCrossRefGoogle Scholar
  38. 38.
    Dickstein K, Cohen-Solal A, Filippatos G, et al. Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of European Society of Cardiology, ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Eur Heart J. 2008;29(19):2388–442. Epub 2008 Sep 17.PubMedCrossRefGoogle Scholar
  39. 39.
    Bayliss J, Norell M, Canepa-Anson R, et al. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J. 1987;57:17–22.PubMedCrossRefGoogle Scholar
  40. 40.
    Vallon V, Miracle C, Thomson S. Adenosine and kidney function: potential implications in patients with heart failure. Eur J Heart Fail. 2008;10:176–87.PubMedCrossRefGoogle Scholar
  41. 41.
    Felker GM, O’Connor CM, Braunwald E, Heart Failure Clinical Research Network Investigators. Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil? Circ. Heart Fail. 2009;2(1):56–62.CrossRefGoogle Scholar
  42. 42.
    Butler J, Forman DE, Abraham WT, et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J. 2004;147(2):331–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Yilmaz MB, Gayat E, Salem R, et al. Impact of diuretic dosing on mortality in acute heart failure using a propensity-matched analysis. Eur J Heart Fail. 2011;13(11):1244–52.PubMedCrossRefGoogle Scholar
  44. 44.
    Metra M, Bugatti S, Bettari L, et al. Can we improve the treatment of congestion in heart failure? Expert Opin Pharmacother. 2011;12(9):1369–79. doi:10.1517/14656566.2011.557069. Epub 2011 Feb 23.PubMedCrossRefGoogle Scholar
  45. 45.••
    Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364(9):797–805. This study is the first large randomized trial assessing efficacy and safety of furosemide in acute heart failure. It compared high versus low dose of furosemide and continuous infusion versus intermittent bolus. High dose was more effective in secondary end points associated with fluid loss, without significant differences in the mean change in creatinine levels from baseline to 72 h. PubMedCrossRefGoogle Scholar
  46. 46.
    Allen LA, Turer AT, Dewald T, et al. Continuous versus bolus dosing of furosemide for patients hospitalized for heart failure. Am J Cardiol. 2010;105:1794–7.PubMedCrossRefGoogle Scholar
  47. 47.
    Thomson MR, Nappi JM, Dunn SP, et al. Continuous versus intermittent infusion of furosemide in acute decompensated heart failure. J Card Fail. 2010;16:188–93.PubMedCrossRefGoogle Scholar
  48. 48.
    Salvator DR, Rey NR, Ramos GC, Punzalan FE. Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database Syst Rev. 2005;3:CD003178–8.Google Scholar
  49. 49.
    Gheorghiade M, Follath F, Ponikowski P, et al. Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail. 2010;12(5):423–33. Epub 2010 Mar 30.PubMedCrossRefGoogle Scholar
  50. 50.
    Ljungman S, Kjekshus J, Swedberg K. Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial). Am J Cardiol. 1992;70:479–87.PubMedCrossRefGoogle Scholar
  51. 51.
    Klein L, Massie BM, Leimberger JD, OPTIME-CHF Investigators, et al. Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF). Circ Heart Fail. 2008;1(1):25–33.PubMedCrossRefGoogle Scholar
  52. 52.
    Friedrich JO, Adhikari N, Herridge MS, Beyene J. Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med. 2005;142:510–24.PubMedGoogle Scholar
  53. 53.
    Giamouzis G, Butler J, Starling RC, et al. Impact of dopamine infusion on renal function in hospitalized heart failure patients: results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial. J Card Fail. 2010;16:922–30.PubMedCrossRefGoogle Scholar
  54. 54.
    Kellum JA, Decker JM. Use of dopamine in acute renal failure: a meta-analysis. Crit Care Med. 2001;29:15231.CrossRefGoogle Scholar
  55. 55.
    Available at NCT01132846Google Scholar
  56. 56.
    Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005;111:1487–91.PubMedCrossRefGoogle Scholar
  57. 57.
    Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA. 2005;293:1900–5.PubMedCrossRefGoogle Scholar
  58. 58.•
    O’Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365(1):32–43. This large randomized trial on nesiritide challenged the use of nesiritide in AHF because it demonstrated a neutral impact of nesiritide on death or rehospitalization, and renal function, and its association with a higher risk of hypotension. PubMedCrossRefGoogle Scholar
  59. 59.
    Lisy O, Huntley BK, McCormick DJ, et al. Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol. 2008;52(1):60–8.PubMedCrossRefGoogle Scholar
  60. 60.
    McKie PM, Sangaralingham SJ, Burnett Jr JC. CD-NP: an innovative designer natriuretic peptide activator of particulate guanylyl cyclase receptors for cardiorenal disease. Curr Heart Fail Rep. 2010;7(3):93–9.PubMedCrossRefGoogle Scholar
  61. 61.
    Pitt B, Zannad F, Remme WJ, for the Randomized Aldactone Evaluation Study Investigators, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709–17.PubMedCrossRefGoogle Scholar
  62. 62.
    Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–21.PubMedCrossRefGoogle Scholar
  63. 63.
    Zannad F, McMurray JJ, Krum H, EMPHASIS-HF Study Group, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11–21. Epub 2010 Nov 14.PubMedCrossRefGoogle Scholar
  64. 64.
    Albaghdadi M, Gheorghiade M, Pitt B. Mineralocorticoid receptor antagonism: therapeutic potential in acute heart failure syndromes. Eur Heart J. 2011;32(21):2626–33. Epub 2011 Jun 14.PubMedCrossRefGoogle Scholar
  65. 65.
    van Vliet AA, Donker AJ, Nauta JJ, Verheugt FW. Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensinconverting enzyme inhibitor. Am J Cardiol. 1993;71:21A–8A.PubMedCrossRefGoogle Scholar
  66. 66.
    Ceremuzynski L, Budaj A, Michorowski B. Single-dose i.v. Aldactone for congestive heart failure: a preliminary observation. Int J Clin Pharmacol Ther Toxicol. 1983;21:417–21.PubMedGoogle Scholar
  67. 67.
    Hensen J, Abraham WT, Durr JA, Schrier RW. Aldosterone in congestive heart failure: analysis of determinants and role in sodium retention. Am J Nephrol. 1991;11:441–6.PubMedCrossRefGoogle Scholar
  68. 68.
    Pitt B, Anker SD, Bushinsky DA, PEARL-HF Investigators, et al. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J. 2011;32(7):820–8. Epub 2011 Jan 5.PubMedCrossRefGoogle Scholar
  69. 69.
    Kamath SA. The role of ultrafiltration in patients with decompensated heart failure. Int J Nephrol. 2010;2011:190230.PubMedGoogle Scholar
  70. 70.
    Ronco C, Giomarelli P. Current and future role of ultrafiltration in CRS. Heart Fail Rev. 2011;16(6):595–602.PubMedCrossRefGoogle Scholar
  71. 71.•
    Costanzo MR, Saltzberg MT, Jessup M, Teerlink JR, Sobotka PA; Ultrafiltration Versus Intravenous Diuretics for Patients Hospitalized for Acute Decompensated Heart Failure (UNLOAD) Investigators. Ultrafiltration is associated with fewer rehospitalizations than continuous diuretic infusion in patients with decompensated heart failure: results from UNLOAD. J Card Fail. 2010;16(4):277–84. Epub 2010 Feb 4. This study compared the outcomes of patients with UF versus intravenous diuretics by continuous infusion or bolus injection. Patients undergoing ultrafiltration showed similar fluid loss and similar renal function compared to those with diuretics, but they had fewer hospitalizations for heart failure.Google Scholar
  72. 72.
    Available at NCT00608491Google Scholar
  73. 73.
    Bradley SM, Levy WC, Veenstra DL. Cost-consequences of ultrafiltration for Acute Heart Failure: a decision model analysis. Circulation. 2009;2(6):566–73.PubMedGoogle Scholar
  74. 74.
    Lee CR, Watkins ML, Patterson JH, et al. Vasopressin: a new target for the treatment of heart failure. Am Heart J. 2003;146:9.PubMedCrossRefGoogle Scholar
  75. 75.
    Udelson JE, Smith WB, Hendrix GH, et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation. 2001;104(20):2417–23.PubMedCrossRefGoogle Scholar
  76. 76.
    Goldsmith SR, Gilbertson DT, Mackedanz SA, Swan SK. Renal effects of conivaptan, furosemide, and the combination in patients with chronic heart failure. J Card Fail. 2011;17(12):982–9. Epub 2011 Oct 6.PubMedCrossRefGoogle Scholar
  77. 77.
    Konstam MA, Gheorghiade M, Burnett Jr JC, Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297(12):1319–31. Epub 2007 Mar 25.PubMedCrossRefGoogle Scholar
  78. 78.
    Gheorghiade M, Gattis WA, O’Connor CM, Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004;291(16):1963–71.PubMedCrossRefGoogle Scholar
  79. 79.
    Slawsky MT, Givertz MM. Rolofylline: a selective adenosine 1 receptor antagonist for the treatment of heart failure. Expert Opin Pharmacother. 2009;10:311–22.PubMedCrossRefGoogle Scholar
  80. 80.
    Gottlieb SS, Brater DC, Thomas I, Havranek E, Bourge R, Goldman S, Dyer F, Gomez M, Bennett D, Ticho B, Beckman E, Abraham WT. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circ. 2002;105:1348–53.CrossRefGoogle Scholar
  81. 81.
    Givertz MM, Massie BM, Fields TK, Pearson LL, Dittrich HC, CKI-201 and CKI-202 Investigators. The effects of KW-3902, an adenosine A1-receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. J Am Coll Cardiol. 2007;50(16):1551–60.PubMedCrossRefGoogle Scholar
  82. 82.
    Voors AA, Dittrich HC, Massie BM, et al. Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function). J Am Coll Cardiol. 2011;57(19):1899–907.PubMedCrossRefGoogle Scholar
  83. 83.•
    Massie BM, O’Connor CM, Metra M, et al.; PROTECT Investigators and Committees. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med. 2010;363(15):1419–28. This trial assessed the effect of the promising A1 adenosine receptor antagonist rolofylline, in patients with AHF and renal dysfunction. Compared to placebo, rolofylline showed no benefits on symptoms, prognosis or renal function. PubMedCrossRefGoogle Scholar
  84. 84.
    Teichman SL, Unemori E, Dschietzig T, et al. Relaxin, a pleiotropic vasodilator for the treatment of heart failure. Heart Fail Rev. 2009;14:321–9.PubMedCrossRefGoogle Scholar
  85. 85.•
    Ponikowski P, Metra M, Teerlink JR, et al. Design of the RELAXin in Acute Heart Failure Study. Am Heart J. 2012;163(2):149–155.e1. This ongoing randomized phase 1/2 clinical trial, following promising results of Pre-RELAX, will provide data about efficacy and safety of relaxin administered at 30 μg/kg/day in patients with AHF, with regard to symptoms, prognosis and renal function. PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Duke Clinical Research InstituteDurhamUSA
  2. 2.Section of Cardiovascular Diseases, Department of Experimental and Applied MedicineUniversity of BresciaBresciaItaly

Personalised recommendations